KLA Invests in Wales
KLA Corporation (NASDAQ: KLAC) shares descended Thursday. The Milpitas, Calif.-based company, a global leader in semiconductor process control and process-enabling technology, today announced the opening of its new $138 million research and development (R&D) and manufacturing center in Newport, Wales, continuing the company's history of regional investment. SPTS, KLA's Wales-based product division, has been leading semiconductor equipment innovation in Wales since 1984, winning multiple Queen's Awards for excellence in R&D and export, and attracting strong technical talent to the region.KLA added the SPTS etch and deposition product lines to its portfolio in 2019, bringing complementary technologies, solutions and services together, and increasing the company's capacity to deliver for customers across the semiconductor industry. Reflecting the portfolio strength and growing customer demand, the new 237,000-square-foot Newport facility provides additional production and customer collaboration spaces, including 25,000 square feet of R&D clean rooms, 35,000 square feet of state-of-the-art manufacturing space and tool demo areas, all designed to support development of semiconductor process technologies across advanced packaging, power devices, microelectromechanical systems, radio frequency and photonics sector technology.With capacity for 750 employees, KLA's new facility is expected to support the continued growth of the electronics ecosystem, serving as a center of engineering and manufacturing excellence, as well as an anchor for the larger community.KLAC shares moved earthward $3.49 to $775.45.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


